SCN SIGNS LICENSE AGREEMENT FOR NEW SUBSTANCE AGAINST OVERWEIGHT

(NGM:SCN)

Scandinavian Clinical Nutrition AB (SCN) has signed an exclusive license agreement with the American company P.L. Thomas & Co for distribution and marketing of the patented substance Xanthigen in Scandinavia. Research has shown that Xanthigen increases the metabolic rate without negative side effects.

SCN plans to launch Xanthigen in Norway, Sweden, Denmark and Finland with an SCN brand name during the first half of 2008. The agreement also includes an option to extend SCN’s rights to the rest of Europe.

Clinical studies on both animals and humans have shown that Xanthigen can increase the metabolic rate with up to 400 kcal per day without the negative central stimulatory side effects that high doses of caffeine, guarana and other similar substances may induce. SCN is now planning to conduct further studies on the substance, together with P.L. Thomas, through the research collaboration that SCN has with Karolinska Institutet (KI).

“Xanthigen is a very interesting product, which gives SCN an exciting possibility to extend our portfolio within the growing weight control subject. We are also looking forward to starting new studies together with P.L. Thomas and KI to develop the product further”, says Ulf Söderberg, CEO of SCN.

SCN already has the weight control product CUUR in the product portfolio, together with a number of other products and substances, targeting areas like common colds and virus related obesity. The company recently entered into an extensive partnership agreement with the American company Inverness Medical Innovations, Inc., to secure the launch of CUUR on the US mass market in time for diet season 2007/2008. Inverness will be responsible for production and distribution into some 70,000 US retail outlets, and in return, SCN will take on the end consumer marketing. CUUR is also being sold in the Nordic countries, and on selected markets in Europe and Asia.

The SCN share is listed for trade on the Swedish OTC list NGM Nordic MTF since December 6, 2006. The company has also applied for listing on the Norwegian Oslo Axess list, on September 26, 2007.

More information:

Ulf Söderberg, CEO, ulf.soderberg@scnutrition.com, +46 708 13 22 81

Anders Struksnes, Senior Vice President, anders.struksnes@scnutrition.com, +47 911 98 942

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Membraseven, Coldizin, Immulina and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth both in Sweden and in the company’s export markets. The SCN share is listed for trade on NGM Nordic MTF since December 6, 2006.